Basilea News http://www.basilea.com/ Basilea News en Fri, 30 Sep 2016 10:22:56 +0200 Fri, 30 Sep 2016 10:22:56 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Unimedic-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-the-Nordic-countries/2950aecd-625d-561b-3949-6c299448a9ae Tue, 20 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Unimedic-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-the-Nordic-countries/2950aecd-625d-561b-3949-6c299448a9ae <![CDATA[Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma]]> http://www.basilea.com/News-and-Media/Basilea-announces-partnership-for-antifungal-isavuconazole-in-Japan-with-Asahi-Kasei-Pharma/aa52f715-2c90-4c7d-1b8a-5aa0979184fb
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

  • ]]>
    Thu, 15 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-partnership-for-antifungal-isavuconazole-in-Japan-with-Asahi-Kasei-Pharma/aa52f715-2c90-4c7d-1b8a-5aa0979184fb
    <![CDATA[Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America]]> http://www.basilea.com/News-and-Media/Basilea-announces-supply-distribution-and-license-agreement-with-Grupo-Biotoscana-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-Latin-America/9cf5b991-223f-8e52-f0c6-d23cda71b4cb Tue, 13 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-supply-distribution-and-license-agreement-with-Grupo-Biotoscana-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-Latin-America/9cf5b991-223f-8e52-f0c6-d23cda71b4cb <![CDATA[Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553]]> http://www.basilea.com/News-and-Media/Basilea-starts-continuous-infusion-phase-1-2a-clinical-study-with-oncology-drug-candidate-BAL101553/0ebb9600-1532-b15d-5f3b-30aa7d534a6b Tue, 06 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-starts-continuous-infusion-phase-1-2a-clinical-study-with-oncology-drug-candidate-BAL101553/0ebb9600-1532-b15d-5f3b-30aa7d534a6b <![CDATA[Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Hikma-for-CRESEMBA-isavuconazole-in-the-MENA-region/75a0847f-c0d8-b2e5-133a-34b99f982bf6
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
  • ]]>
    Wed, 17 Aug 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Hikma-for-CRESEMBA-isavuconazole-in-the-MENA-region/75a0847f-c0d8-b2e5-133a-34b99f982bf6
    <![CDATA[Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets]]> http://www.basilea.com/News-and-Media/Basilea-reports-2016-half-year-results-CRESEMBA-launched-in-key-European-markets/af0d2479-4963-6f53-99b2-85dae0ce489b
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
  • ]]>
    Mon, 15 Aug 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-2016-half-year-results-CRESEMBA-launched-in-key-European-markets/af0d2479-4963-6f53-99b2-85dae0ce489b
    <![CDATA[Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy]]> http://www.basilea.com/News-and-Media/Basileas-antifungal-CRESEMBA-isavuconazole-launched-in-Italy/20f7ff0b-bd95-beb9-6ae6-122f352d592a Mon, 27 Jun 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-antifungal-CRESEMBA-isavuconazole-launched-in-Italy/20f7ff0b-bd95-beb9-6ae6-122f352d592a <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-ASCO-meeting/0ac65095-e31b-3ee8-d3fc-2821b95d15f8
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
  • ]]>
    Thu, 09 Jun 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-ASCO-meeting/0ac65095-e31b-3ee8-d3fc-2821b95d15f8
    <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 Thu, 21 Apr 2016 18:30:10 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4